The company announced its June quarter results on July 25, 2020 during which it reported a 280.62 per cent year-on-year (YoY) jump in net profit to Rs 85.45 crore as against Rs 22.45 crore during the previous quarter ended June 2019.
The company's consolidated revenue for the quarter came in at Rs 544.67 crore, up 34.34 per cent YoY, with 85 per cent and 15 per cent contribution from API segment and formulation, respectively.
Domestic sales of the API segment grew 28 per cent and exports by 29 per cent. Around 50 per cent of the YoY growth in the API segment was due to volume growth. Formulation segment revenues grew by around 89 per cent YoY on the account of high export growth.
Consolidated earnings before interest, tax, depreciation, and ammortisation (Ebitda) for the quarter stood at Rs 135 crore, up 147 per cent YoY. Consolidated Ebitda margin improved to 24.83 per cent.
The company said it has planned additional CAPEX for introducing new products in anti-diabetic category towards the end of FY21.